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Background: Gene therapy has been an attractive paradigm for cancer treatment. However, cancer gene therapy
has been challenged by the inherent limitation of vectors that are able to deliver therapeutic genes to tumors
specifically and efficiently following systemic administration. Bacteriophage (phage) are viruses that have shown
promise for targeted systemic gene delivery. Yet, they are considered poor vectors for gene transfer. Recently, we
generated a tumor-targeted phage named adeno-associated virus/phage (AAVP), which is a filamentous phage
particle whose genome contains the adeno-associated virus genome. Its effectiveness in delivering therapeutic genes
to tumors specifically both in vitro and in vivo has been shown in numerous studies. Despite being a clinically useful
vector, a multitude of barriers impede gene transduction to tumor cells. We hypothesized that one such factor is the
tumor extracellular matrix (ECM).
Methods: We used a number of tumor cell lines from different species and histological types in 2D monolayers or 3D
multicellular tumor spheroid (MCTS) models. To assess whether the ECM is a barrier to tumor cell targeting by AAVP,
we depleted the ECM using collagenase, hyaluronidase, or combination of both. We employed multiple techniques
to investigate and quantify the effect of ECM depletion on ECM composition (including collagen type I, hyaluronic
acid, fibronectin and laminin), and how AAVP adsorption, internalisation, gene expression and therapeutic efficacy are
subsequently affected. Data were analyzed using a student’s t test when comparing two groups or one-way ANOVA
and post hoc Tukey tests when using more than two groups.
Results: We demonstrate that collagenase and hyaluronidase-mediated degradation of tumor ECM affects the
composition of collagen, hyaluronic acid and fibronectin. Consequently, AAVP diffusion, internalisation, gene
expression and tumor cell killing were enhanced after enzymatic treatment. Our data suggest that enhancement of
gene transfer by the AAVP is solely attributed to ECM depletion. We provide substantial evidence that ECM modulation
is relevant in clinically applicable settings by using 3D MCTS, which simulates in vivo environments more accurately.
Conclusion: Our findings suggest that ECM depletion is an effective strategy to enhance the efficiency of viral
vector-guided gene therapy.
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Cancer is a complex genetic disease that results in
malignancy of native tissue [1]. Gene therapy was initially
conceived as an approach for treating genetic diseases;
however, its scope has expanded to include treatments for
cancer [2]. Currently, over 60 % of ongoing clinical gene
therapy trials are designed to treat cancer [3]. Most cancer
gene therapy vectors are invasively administered via intra-
tumoral injections, and the development of non-invasive
systemic vectors are greatly warranted. In addition to
potentially causing less harm to the patient, it may target
both localized and metastatic tumors. Successful cancer
gene therapy depends on the development of vectors able
to deliver therapeutic genes to tumors specifically and
efficiently, while sparing healthy tissues. Animal viruses
have the potential to be developed for targeted gene
transfer, but require elimination of their native tropism for
mammalian cells [4]. This approach however, is challenging
because engineering viruses to target non-natural receptors
greatly reduce their efficiency [5].
We have previously reported the generation of a
hybrid bacteriophage vector for targeted systemic
cancer gene therapy and molecular imaging [6]. This con-
struct, termed (adeno-associated virus/phage) AAVP, is a
combination of a mammalian transgene cassette flanked
by inverted terminal repeats (ITRs) from adeno-associated
virus 2 (AAV2) and a fUSE-5 (peptide display) vector
derived from the fd bacteriophage genome. Phages
have evolved to infect bacteria only and thus, unlike
eukaryotic viruses, have no strategies to deliver genes
to mammalian cells. The AAVP displays the cyclic RGD4C
(CDCRGDCFC) fusion peptide on its pIII capsid protein,
allowing homing to and entry via αv integrin receptors
such as αvβ3 and αvβ5, which are expressed by cancer cells
or cancer-associated endothelial cells, but not on
normal tissues or vasculature [7, 8]. Moreover, the
RGD4C.AAVP construct has allowed for drastic im-
provements in gene delivery rates to cancer cells over
conventional bacteriophage vectors, as shown in nu-
merous in vitro and in vivo studies, including a
large-scale cancer trial involving pet dogs with natural
cancers [9]. Even though the targeting and efficiency of
the RGD4C.AAVP has improved with the modifica-
tions applied thus far, there still exists a large room for
improvement.
An important consideration is not all limitations are
attributable to the vector. Cancer cells in particular,
possess macro- and microanatomical barriers that impede
gene delivery. Specifically, desmoplastic reactions result in
substantial extracellular matrix (ECM) formation around
tumors, cancer-associated fibroblasts and infiltrating
immune cells [10]. The resultant high interstitial fluid
pressure (IFP), spatial hindrance and inhibition of
cell-surface receptors decrease uptake of therapeutics [11].As such, depletion of the ECM before administration of
therapeutics constitutes a mechanism for tumor priming
[12]. ECM clearance should allow increased transport and
binding of RGD4C.AAVP to αv integrin receptors on the
tumor cell surface. This principle of transduction has
already been demonstrated in multiple studies through
the use of ECM-depleting enzymes [13–15].
We sought to test the hypothesis that ECM depletion can
increase the tumor transduction efficacy of RGD4C.AAVP
vectors by evaluating the effects of co-administering AAVPs
after treatment of cancer cells with collagenase, hyaluroni-
dase or a combination of both. Our results show that ECM
degradation is a powerful adjuvant in raising transduction
rates for phage-guided cancer therapy. These findings were
further verified through RGD4C.AAVP-mediated cancer
killing by delivering the conditionally toxic Herpes simplex
virus-thymine kinase (HSVtk) suicide gene in conjunction
with ganciclovir treatment. We have also validated this
strategy through a multicellular tumor spheroid model
(MCTS). Our results demonstrate how modulating the
tumor microenvironment may enhance the efficacy of
RGD4C.AAVP and other gene delivery vectors as powerful
implements against cancer.
Results
Treatment of tumor cells by collagenase and
hyaluronidase affects tumor ECM composition
Firstly, it is important to determine the composition of
ECM constituents after treatment of tumor cells by
collagenase, hyaluronidase, or a combination of both.
We selected three candidate tumor cell lines − 9L rat
gliosarcoma, as well as human MCF-7 breast cancer
and human LNCaP prostate cancer for evaluation.
Qualitative analysis of changes in fibronectin and
laminin post-enzymatic treatment was performed by
immunostaining using anti-fibronectin or anti-laminin
antibodies. We consistently observed a significant decrease
in fibronectin expression, but not laminin, post-collagenase
or collagenase plus hyaluronidase treatments of LNCaP
cells (Fig. 1), as well as 9L and MCF-7 cells (data not
shown). Conversely, we observed no differences in
fluorescence of cells after treatment with hyaluronidase
alone, indicating that the decrease in fibronectin, as
indicated by fluorescence, is attributable to collagenase
treatment (Fig. 1).
Moreover, we quantified the presence of type I collagen
and hyaluronic acid (hyaluronan, HA) in the supernatants
of cells after treatment with collagenase, hyaluronidase or
both using colorimetric assays in 2D cell monolayers and
3D MCTS. HA levels were quantified by an optimized
ELISA protocol for HA detection using biotinylated
HA binding proteins (Fig. 2a). Collagen was quantified
using a Sirius Red assay before and after enzymatic treat-
ment (Fig. 2b).
Fig. 1 Immunostaining of fibronectin and laminin in LNCaP cells after ECM depletion. LNCaP cells were treated with collagenase, hyaluronidase
or a combination of both enzymes before incubation with mouse anti-fibronectin (Anti-Fn) or mouse anti-laminin (Anti-Ln) antibodies, followed
by goat anti-mouse AlexaFluor 488-conjugated secondary antibody. Depletion of fibronectin after treatment with collagenase or a combination
of both enzymes, but not with hyaluronidase alone was clearly observed. No observable differences could be seen for laminin. Experiments including
secondary antibody alone were used as negative controls. Data shown are representative of all three cell lines tested (LNCaP, 9L and MCF-7).
Experiments were repeated twice and individual conditions were repeated in triplicates
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hyaluronidase and collagenase, the concentration of HA in
the supernatant was 4000-4025 ng/ml for 2D monolayer
and 6673-7378 ng/ml for 3D MCTS, excluding 9L MCTS,
which released only 64 % of HA relative to combined
treatment (Fig. 2A). Interestingly, only 9L cells released
relatively higher levels of HA after treatment with collage-
nase alone in both 2D and 3D cultures (2987 ng/ml and
2551 ng/ml, respectively). In 2D cultures however, MCF-7
and LNCaP cells both released 552 ng/ml HA after
treatment with collagenase, but not in 3D cultures.
The reported concentration of collagen in the
supernatant of MCF-7, LNCaP and 9L cells ranged
between 580-724 μg/ml for 2D monolayer cultures
and 390-493 μg/ml for the 3D MCTS following treat-
ments with collagenase or combination of collagenase plus
hyaluronidase, as compared to baseline measurements
(Fig. 2B). Baseline collagen concentrations after treatment
with hyaluronidase were negligible for 2D monolayers;
however, in 3D MCTS, MCF-7 and LNCaP cell lines
increased collagen release in to the supernatant, 207
and 272 μg/ml, respectively, upon hyaluronidase treat-
ment alone.
Removal of ECM proteins enhances diffusion and
internalization of RGD4C.AAVP
After establishing that enzymatic treatment depletes
specific ECM constituents, we aimed to investigate
how it may affect diffusion and cell internalization
of RGD4C.AAVP. We performed a RGD4C.AAVP
diffusion assay and assessed the effect of ECM deple-
tion on RGD4C.AAVP internalization in 9L rat gliosar-
coma cells.We investigated the movement of RGD4C.AAVP
through ECM matrices at different concentrations by using
confocal microscopy, and observed that fluorescently-
labeled RGD4C.AAVP particles had greater diffusion
when introduced into lower concentrations of ECM-gel
matrix compared to higher concentrations (Fig. 3a).
Fluorescently-tagged RGD4C.AAVP moved through the
2.5 mg/ml ECM 2.6 times faster and covered an area 3
times larger when compared to the 5.0 mg/ml one
(Fig. 3b). These findings suggest that physical interactions
of the RGD4C.AAVP particles with the tumor micro-
environment create significant obstacles for phage-guided
gene transfer.
Next, we determined whether ECM in the microenviron-
ment could be manipulated to increase cellular uptake of
RGD4C.AAVP after treatment with the ECM-degrading
enzymes. An RGD4C.AAVP internalization assay was
performed by which the intracellular post-transduction
RGD4C.AAVP was quantified by flow cytometry. Figure 3c
depicts significant enhancement of RGD4C.AAVP
endocytosis in 9L tumor cells following ECM removal
compared to control treatment with RGD4C.AAVP alone
(without enzymatic ECM depletion). Combination
treatment with both collagenase and hyaluronidase
allowed up to 37 % increase in RGD4C.AAVP internaliza-
tion, reflected by higher intracellular RGD4C.AAVP signal
as well as enhanced RGD4C.AAVP signal counts per
10,000 cells (Fig. 3d). Interestingly, ECM depletion did not
affect the specificity of RGD4C.AAVP cancer cell internal-
ization as no effect was observed on the control non-
targeted NT.AAVP (Fig. 3c). These data demonstrate the
role of the ECM as a physical barrier to successful
RGD4C.AAVP entry into cancer cells.
Fig. 2 Hyaluronic acid ELISA and Collagen Sirius red assay of cell culture media after collagenase and hyaluronidase treatments of 2D cell
monolayers and MCTS of MCF-7, LNCaP and 9L. Cell monolayers or MCTS were treated with hyaluronidase or collagenase, or combination of both
enzymes before the culture supernatants were analysed for hyaluronic acid (hyaluronan, HA) or collagen (type I). a Hyaluronic acid ELISA was based on
adding biotinylated HA binding proteins to a plate coated with umbilical cord HA and subsequent treatment with peroxidase-conjugated anti-biotin
antibodies. The results, show release of HA in to the culture medium primarily after treatment with hyaluronidase or a combination of both enzymes.
b Sirius Red assay (chondrex) results showing release of collagen in to the culture medium primarily after treatment with collagenase or a combination
of both enzymes. Experiments were repeated twice and individual conditions were repeated in triplicates. Data are presented as mean ± s.e.m
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rins on the target cell for successful binding and internal-
ization, we performed immunostaining on 9L cells to
confirm expression of this tumor specific integrin to allow
endocytosis (Fig. 4). The mouse C2C12 myoblast cells
were used as negative control, as they do not express
αv integrins [16]. The results show that 9L cells express αv
integrins, but not the C2C12 cells. Additionally, it has been
previously demonstrated that all cell lines we used in this
study express αv integrins [17–22].
ECM depletion significantly increases targeted gene
transfer by RGD4C.AAVP
Having shown that ECM degradation increased the
cell accessibility and entry of RGD4C.AAVP vectors
in cancer cells, we sought to determine if enhanced
endocytosis translates to increased gene expression.
9L cells were transduced with RGD4C.AAVP/GFP orRGD4C.AAVP/Luc, carrying the green fluorescent protein
(GFP) or the firefly Luc reporter genes. Various ECM
depleted conditions were tested including collagenase,
hyaluronidase, or a combination of both enzymes.
Firstly, quantification of gene expression was done using
the RGD4C.AAVP/Luc vector 72 h post-transduction and
a luciferase assay kit (Steady-Glo, Promega). To determine
optimum concentrations of collagenase and hyaluronidase
enzymes for use in future experiments, we carried out a
titration experiment with increasing concentrations of both
enzymes in 9L tumor cells (Fig. 5a). Levels of collagenase
or hyaluronidase (0 mg/ml to 0.5 mg/ml) were tested for
effects on RGD4C.AAVP-mediated Luc gene expression
(Fig. 5a). In 9L cells, increasing collagenase levels re-
sulted in enhanced gene expression by RGD4C.AAVP,
peaking at 0.2 mg/ml and dropping at higher concen-
trations, whereas hyaluronidase application was most
effective at 0.4 mg/ml (Fig. 5a).
Fig. 4 Immunostaining of αv integrins in 9L cells. Cells seeded on coverslips were fixed and immunofluorescence stained using rabbit anti-αv-integrin
primary and goat anti-rabbit AlexaFluor-488 secondary antibodies. The αv integrin-associated fluorescence is shown in green and nuclei (DAPI) in blue.
Experiments were repeated three times. The mouse C2C12 myoblasts were included in this experiment as negative control for αv integrin expression
Fig. 3 Cellular diffusion and internalization of RGD4C.AAVP is boosted by ECM clearance. a RGD4C.AAVP diffusion assay was carried out using
fluorescently-labelled RGD4C.AAVP and followed through an ECM gel matrix. Two ECM concentrations were tested (2.5 and 5.0 mg/ml) and
RGD4C.AAVP was tracked using fluorescent microscopy. b Measurement of RGD4C.AAVP diffusion, per fields of view (FOV), at various time points
for a total time of 6 h. c Flow cytometric analysis of AAVP uptake was performed in 9L cells after ECM depletion. Cells were treated either with
a combination mix of collagenase (0.2 mg/ml) and hyaluronidase (0.4 mg/ml) or without any enzyme (control) for 1 h before incubation with
either non-targeted NT.AAVP (white bars) or RGD4C.AAVP (black bars). Fixation was conducted 4 h post-transduction and immunofluorescence
was performed using rabbit anti-phage primary and goat anti-rabbit AlexaFluor-647 conjugated antibodies. Gating threshold was set at 10,000
events of total cell population. Each condition was measured in triplicate and statistics were obtained by unpaired student t-test (** = p < 0.01).
Data are presented as mean ± s.e.m. d The graph shows shifts in mean fluorescence intensity and RGD4C.AAVP positive cell counts between
no-enzyme control (yellow line) and enzyme combination treatment (blue line). Experiments were repeated twice and individual conditions
were repeated in triplicates
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Fig. 5 Characterization of the effect of ECM depletion on RGD4C.AAVP-guided gene transfer in 9L cells. a Luciferase expression in 9L cells by
Steady-Glo® assay after treatment with increasing concentrations of collagenase or hyaluronidase, at day 3 post-transduction with RGD4C.AAVP/
Luc vector carrying the Luc reporter gene. b Time course expression of luciferase over 5 days post transduction with RGD4C.AAVP vector alone, or
RGD4C.AAVP in conjunction with collagenase (0.2 mg/ml) or hyaluronidase (0.4 mg/ml) or with combination of both enzymes. Similar enzymatic
treatments were included with the control non-targeted NT.AAVP vector. c GFP expression in 9L cells transduced with RGD4C.AAVP-GFP alone
(control) or following various ECM depletion strategies: collagenase, hyaluronidase or combination of both enzymes. Images were visualized by
fluorescence confocal microscopy 3 days post vector transduction One way ANOVA was used, together with Tukey’s post-test to generate the
data, *, p < 0.05, **, p < 0.01, ***, p < 0.001. Luciferase expression results are shown as relative luminescence units/1 μg protein. Samples were
obtained through triplicate wells and each experiment was performed at least twice with consistent results. Data are presented as mean ±
s.e.m. Experiments were repeated twice and individual conditions were repeated in triplicates
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expression is a transient or a long-term effect. We
further determined in 9L cells, the changes in gene ex-
pression over time (5 days post vector transduction)
through sequential luciferase assays (Fig. 5b). Differences
in gene expression between the control RGD4C.AAVP
alone and the combination enzyme treatment were
significantly detectable from as early as day 2 after trans-
duction, where a 1.9-fold higher Luc expression was de-
tected in combination with ECM depletion by both
collagenase and hyaluronidase enzymes (Fig. 5b). Luc ex-
pression in all groups continued to increase throughout
the experimental timeframe and strong differences be-
tween treatment groups were clearly visible 5 days post
transduction. Transgene expression levels in the com-
bination treatment group reached a substantial 6.7-fold
increase when compared to RGD4C.AAVP alone by day
5. Importantly, non-targeted NT.AAVP vector (lacking
RGD4C ligand) was unable to achieve gene expression
alone or in combination with ECM depletion (Fig. 5b)confirming that specificity is preserved when combining
RGD4C.AAVP and ECM degradation.
Even though the biggest differences between treatment
groups were clearly observed when transgene expression
was allowed to run its course well past 72 h, further
experiments were conducted with a 3-day limit to strike
a balance between experiment turnover rate and any
observable effects from ECM depletion. These experi-
ments demonstrate that ECM degradation can result
in long-lasting enhanced gene expression from the
RGD4C.AAVP vector.
Finally, to qualitatively demonstrate the effect of
ECM depletion on phage-guided gene transfer, we
assessed GFP expression using RGD4C.AAVP/GFP
vectors after enzymatic treatment (Fig. 5c). Based on
the optimal enzyme concentrations found in Fig. 5a,
confocal microscopic analysis of transgene expression
72 h post-transduction using RGD4C.AAVP/GFP
vector in combination with ECM depletion supported
the results obtained from the luciferase assay. As we
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centrations resulted in an even higher GFP expression
compared to that of each enzyme alone (Fig. 5c).
Gene expression in 3D multicellular tumor spheroids
(MCTS) of 9L cells
MCTS are increasingly recognized as superior tools over
traditional 2D monolayer cell culture systems as they are
able to mimic in vivo tumor microenvironements better
[23]. Because tumor spheroids are much more complex
than tumor cell monolayers, we postulated that the gene
expression profile after treatment of ECM-depleting
enzymes should be different. A range of collagenase or
hyaluronidase concentrations (0 mg/ml, 0.04 mg/ml,
0.2 mg/ml, 1 mg/ml and 5 mg/ml) were tested on 9L
MCTS followed by RGD4C.AAVP/Luc transduction and
a luciferase assay (Fig. 6a).
Highest levels of luciferase expression were observed
with 0.2 mg/ml of collagenase and 1 mg/ml of hyaluroni-
dase with gene expression dropping in proportion to in-
crease in enzyme concentration (Figs. 6a). These optimal
concentrations were used in further tests combining both
collagenase and hyaluronidase in treating 9L MCTS,
showing a significant 2.6-fold increase of Luc transgene
expression over control without ECM depletion (Fig. 6b).
RGD4C.AAVP/HSVtk and GCV treatment in ECM depleted
conditions results in increased tumor cell killing
To investigate whether increased transgene expression by
RGD4C.AAVP in ECM depleted conditions could trans-
late into enhanced cancer gene therapy, we incorporated
in AAVP vectors the HSVtk cytotoxic gene, whose productFig. 6 Multicellular tumor spheroid (MCTS) models showed increased targ
depletion. a Concentration gradient curves of ECM degrading collagenas
of post-transduction day 3 Luc gene expression through Steady-Glo® assa
or hyaluronidase treatments. b Quantification of RGD4C.AAVP-mediated lucifera
concentrations of collagenase (0.2 mg/ml) or hyaluronidase (1 mg/ml). RGD4C.A
experiments used triplicates for samples and were conducted at least twice. Luc
protein and presented as mean ± s.e.m.. One way ANOVA with Tukey’s post-tes
made comparisons between control and combination treatment, *, p < 0.05, **,
conditions were repeated in triplicatesactivates the cytotoxic pro-drug ganciclovir (GCV).
Addition of GCV to HSVtk-expressing cells induces cell
death, as HSVtk expression results in formation of GCV-
triphosphate, which is a chain terminating nucleoside
analogue [24]. In these experiments, treatment with ECM-
depleting enzymes was first carried out, then GCV treat-
ment was initiated 72 h post RGD4C.AAVP transduction
to allow sufficient HSVtk expression. Four cell lines were
used to evaluate ECM depletion as a strategy to enhance
therapeutic efficacy of RGD4C.AAVP, including 9L,
M21 (human melanoma), U87 and SNB19 (human glio-
blastoma). Cell killing was assessed by quantification of
dead cells using the trypan blue exclusion method.
We consistently observed a significant drop in cancer cell
viability after combination enzyme treatment when com-
pared to RGD4C.AAVP alone, across all four cell lines. 9L
experienced the most significant drop by 63.0 % (Fig. 7a),
followed by M21 (61.4 %, Fig. 7c), U87 (41.2 %, Fig. 7d) and
SNB19 (33.2 %, Fig. 7b). In groups treated with either
collagenase or hyaluronidase, a general drop in cell-viability
was consistently observed when compared to RGD4C.AAVP
alone, but was only significant for M21, 9L and U87 cell-
lines. The decrease in cell-viability after treatment with either
collagenase or hyaluronidase alone did not consistently
produce significant drops compared to each other, but
followed the general trend of decreased cell-viability com-
pared to the group with no enzyme treatment.
ECM depletion by enzymatic treatment does not affect
cell viability
We sought to verify that tumor cell viability is not
affected by enzymatic treatment, in order to confirmeted gene transfer by RGD4C.AAVP in combination with ECM
e or hyaluronidase enzymes in 9L MCTS generated by quantification
y. RGD4C.AAVP/Luc was applied to cells that underwent collagenase
se expression in 9L MCTS following treatment with combination of optimal
AVP/Luc alone, without enzymes, was included as control treatment. All
iferase expression results are shown as relative luminescence units/1 μg
t was used for the concentration curve whereas unpaired student’s t-test
p < 0.01, ***, p < 0.001. Experiments were repeated twice and individual
Fig. 7 ECM depletion results in significant cell killing effects by RGD4C.AAVP-mediated HSVtk/GCV gene therapy. Cell viability of a) 9L rat
gliosarcoma, b) SNB19 human glioblastoma, c) M21 human melanoma and d) U87 human glioblastoma measured after ECM treatment in
conjunction with transduction by targeted RGD4C.AAVP or non-targeted NT.AAVP carrying the HSVtk transgene. The GCV (40 μM) was applied
for 3 days and renewed daily starting 72 h after vector transduction. Cell killing was quantified by the trypan blue exclusion method and data
expressed as percentage of control cells that were not treated with AAVP vectors. Data show the means of triplicate samples. A representative
experiment is shown, and experiments were repeated three times with similar results. Statistics were performed by one way ANOVA with
application of Tukey’s post-test, *, p < 0.05. Data are presented as mean ± s.e.m. Individual conditions were repeated in triplicates
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HSVtk plus GCV is the result of increased HSVtk gene
expression. Therefore, we established a stable cell popu-
lation expressing HSVtk by transducing M21 cells with
RGD4C.AAVP/HSVtk containing the puromycin selec-
tion gene (termed M21-tk). Next, the stable cell popula-
tion was treated with collagenase, hyaluronidase or a
combination of both enzymes at several weeks after the
initial treatment with RGD4C.AAVP/HSVtk, to exclude
the presence of RGD4C.AAVP particles. Treatment with
GCV started 72 h after enzyme treatment. Using a cell
viability assay, we observed a significant drop in cell
viability in M21-tk by approximately 50 % compared to
parental non-transduced M21 cells (Fig. 8). Importantly,
there was no detectable effect of ECM depletion on the
viability of parental M21 cells. There were no significant
differences between cell viability across treatments
groups of M21-tk cell population. Taken together, these
data indicate that enzymatic treatments with collagenase
or hyaluronidase or combination of both do not affect
viability of cells and that differences in cell viability after
RGD4C.AAVP therapy are due to improved vector diffu-
sion through the ECM and subsequently enhanced
tumor cell transduction by RGD4C.AAVP, but not
enzymatic treatment.ECM depletion through losartan enhances transduction
by RGD4C.AAVP
To determine whether ECM depletion through drug
treatment will have similar effects on gene transduc-
tion by RGD4C.AAVP as enzyme treatment, we used
losartan, a FDA-approved (Food and Drug Administration,
US) antihypertensive that also inhibits collagen I syn-
thesis, to deplete collagen in 9L cells [25]. Luciferase
reporter assays were repeated to determine whether
losartan could be a possible replacement for collagenase.
When pre-treated with losartan at an optimal concentra-
tion (100 μM), the transduction efficiency of RGD4C.AAVP
was significantly enhanced, peaking at 4.0 × 106 relative
luminescence units, which is approximately 2.4-fold higher
than the control group with no losartan added (Fig. 9).
Again losartan didn’t affect the tumor cell specificity of the
RGD4C.AAVP since the control non-targeted NT.AAVP
was unable to deliver gene expression in the presence of
losartan.
Discussion
In this study, we demonstrate the effectiveness of ECM
depletion as a strategy to enhance bacteriophage-guided
gene transfer to cancer cells. By removing various ECM
constituents using collagenase, hyaluronidase or a
Fig. 8 ECM depletion does not have an intrinsic effect on tumor cell
viability. The M21 tumor cells were transduced with RGD4C.AAVP/
HSVtk-puroR containing the HSVtk and a puromycin resistant gene.
At day 3 post vector transduction, cells were diluted and grown in
puromycin- containing medium. At day 14 post vector transduction,
M21 puromycin resistant cell clones were pooled as a population
stably expressing HSVtk (M21-tk) and grown for a few weeks. Next, the
M21-tk as well as parental M21 cells were subjected to enzymatic
treatments with hyaluronidase or collagenase, or combination of both.
GCV treatment started the next day and was carried out for 3 days.
Evaluation of cell viability was performed by using the CellTiter Glo.
Data show the mean of triplicate samples and are expressed as the
percentage of parental M21 cells. A representative experiment is
shown, and experiments were repeated twice with similar results.
Statistics were performed by one way ANOVA with application of
Tukey’s post-test, *, p < 0.05. Data are presented as mean ± s.e.m.
Experiments were repeated twice and individual conditions were
repeated in triplicates
Fig. 9 Losartan-mediated effects on RGD4C.AAVP transduction. 9L
cells were incubated overnight with increasing concentrations
20 μM, 50 μM, 100 μM, 150 μM, 200 μM of losartan and transduced
the following day with targeted RGD4C.AAVP or non-targeted
NT.AAVP vectors expressing the Luc gene. Luc gene expression was
quantified 3 days post-transduction by the luciferase Steady-Glo®
assay kit. Means from triplicates are shown while the graph is
representative of similar experiments (n = 2). One way ANOVA with
application of Tukey’s post-test, *, p < 0.05, was performed to
determine conditions for maximal transduction success rate. Data
are presented as mean ± s.e.m. Experiments were repeated twice
and individual conditions were repeated in triplicates
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RGD4C.AAVP internalization and RGD4C.AAVP-mediated
gene expression, leading to enhanced therapeutic efficacy.
The most dramatic effect was observed when various
tumor cell lines were treated with a combination of both
enzymes in both 2D and 3D MCTS settings.
The data provide evidence that a combination of
spatial and biochemical changes are responsible for the
increase in gene transfer efficacy following enzyme-
induced ECM depletion. Because the tumor ECM is a
primary obstacle that impedes therapy from reaching
target cells, when ECM is depleted, the spatial distribu-
tion and adsorption of RGD4C.AAVP vectors on the
tumor cell surface are improved. Furthermore, ECM
constituents may also biochemically impede vector
access to tumor cells. Two interesting ECM constituents
that had the highest impact in terms of competitive
inhibition are collagen and fibronectin; both of these
constituents are ligands for αv integrins which are alsothe receptor targets of the RGD4C ligand displayed on
RGD4C.AAVP and substantially decreased following
enzymatic treatment [26, 27]. Our data also show that
hyaluronic acid was also released by enzyme treatment;
however, it has not been shown that it may compete or
interact with αv integrin receptors. These data suggest
that enhanced gene expression by RGD4C.AAVP vectors
after enzyme-mediated ECM depletion is a function of
both physical and biochemical changes in the ECM.
When judging the effect of ECM depletion on
RGD4C.AAVP gene therapy, it is crucial to consider
gene transduction at all stages. Unlike drug molecules,
RGD4C.AAVP cannot easily diffuse through the ECM;
it is a relatively narrow (6.5 nm width) elongated cylin-
der reaching up to 1400 nm length [28] making cellular
access difficult in the presence of ECM. Additionally,
the ECM is hydrophilic, subsequently increasing the
relative volume of the microenvironment surrounding
tumor cells.
Our experiments provide the first proof of concept
evidence that ECM clearance can be used in phage-
guided gene transfer to improve targeted cancer cell
killing. As we have shown, collagenase and hyaluroni-
dase are able to substantially increase RGD4C.AAVP-
mediated gene transfer efficacy in cancer cells and exert
additive effects when both are applied. These effects can be
explained, as collagen and hyaluronic acid are separate
ECM constituents that may inhibit vector transduction in
various ways. However, high levels of enzymes, especially
collagenase, seem to be counterproductive to transduction.
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cells during washing, rather than a direct alteration of cellu-
lar function due to enzyme-treatment.
Administration of collagenase into tumor-bearing
animal models has been proven to decrease the intersti-
tial fluid pressure and improve gene therapy vector
accessibility as well as transduction [29]. Despite FDA-
approved use as a locally injected treatment in man [30],
intravenous administration of collagenase remains a
particular concern since they do not discriminate
between healthy and diseased tissues. As a result, injec-
tions may cause tissue damage, as demonstrated by lung
necrosis and hemorrhages in murine models [31]. More-
over, the ECM has been implicated in many cancer path-
ways including metastasis [32]. High levels of interstitial
matrix metalloproteinases (MMPs), specially collagenase,
have been found to correlate with poorer prognosis and
increased metastatic potential for some cancers [33].
Therefore, the clinical translatability of ECM depletion
as a strategy to enhance cancer therapy warrants further
investigation.
One potential way of circumventing systemic ECM deg-
radation is to use a pharmacological agent to inhibit its pro-
duction. Losartan is a candidate angiotensin II type I
receptor antagonist for hypertension, which has shown
anti-fibrotic activity mediated by the Tumor Growth Factor
Beta 1 pathway through thrombospondin-1 (TSP-1), lead-
ing to inhibition of collagen type I synthesis [34, 35]. Its
combination with oncolytic HSV has been efficacious in
murine xenograft models of human cancers, and has shown
limited and manageable side effects in patients [14, 36], of-
fering a better safety profile than intravenous collagenase.
Losartan’s mechanism of action inhibits new synthesis of
collagen rather than degrading collagen, meaning it
may preferably affect more metabolically active cancer
cells. Furthermore, losartan has potentially multiple
anti-cancer properties such as metastatic suppression
via TGF-β1 signaling [37] that make it especially at-
tractive for use in this field. Thus, drug modulation of
collagen may provide an alternative strategy for enhan-
cing gene transfer in cancer. In our study we showed
that losartan produced a significant gene expression in-
crease by RGD4C.AAVP vector without affecting its
tumor cell specificity.
While we observed changes in multiple ECM con-
stituents, fibronectin is clearly affected after treatment
with collagenase. Multiple studies have shown that
fibronectin synthesis is positively related to progres-
sion and metastases of cancer [38]. Suppression of
growth factor signaling pathways can down-regulate
fibronectin synthesis, and is a potential strategy for
enhancing penetration of vector/cell-based therapies
to solid tumors [39–41]. Direct or indirect inhibition
of fibronectin will significantly contribute to enhancedtherapy, as it is a physical barrier to tumor cells, in
addition to being competitive inhibitor of receptors
that RGD4C.AAVP vectors use for tumor cell entry
[26]. Our data suggest that down-regulation of fibro-
nectin, combined with collagen, may significantly
account for increased gene expression from the
RGD4C.AAVP vector; indeed, this is supported by pre-
viously reported in vivo data for other gene therapy
vectors [42]. Strategies to inhibit fibronectin synthesis
or degrade existing tumor-associated fibronectin are
crucial in the context of ECM depletion in gene
therapy vectors, including RGD4C.AAVP.
Though we have focused on collagen and fibronectin
as the main inhibitory ECM constituents, therapies
involving hyaluronidase are also used in clinical settings.
Intravenous hyaluronidase has already been used as a
safe drug for myocardial infarction in man [43].
Different levels of hyaluronidase have been associated
with both cancer growth and suppression with some
studies showing tumor-associated production of the
enzyme, whereas others have shown that higher concen-
trations inhibit tumorigenesis. This suggests the poten-
tial role of hyaluronidase as an adjuvant for breast
cancer chemotherapy [44]. Though efficacious, it has not
found widespread use due to its immunogenicity, as it is
of bovine origin [45]. However, a recently FDA-approved
recombinant human hyaluronidase (PEGPH20, Halozyme
Therapeutics) is being evaluated in an ongoing trial for
patients with advanced solid tumors [46, 47], suggesting
that hyaluronidase can be a clinically feasible anti-cancer
adjuvant.
Alternative strategies for decreasing hyaluronic acid
production, such as enzyme inhibition have also been
considered. Inhibition of hyaluronic acid synthase (HAS)
using antisense oligonucleotides has been used in murine
in vivo models to halt cancer progression [48]. Another
small molecule HAS inhibitor, 4-methylumbelliferone has
even shown anticancer effects independent of ECM deple-
tion effects, consequently reducing proliferation and
cellular metastatic potential [49].
We have also demonstrated the feasibility of ECM de-
pletion in 3D MCTS, which are thought to be superior
models for in vivo tumors [50]. The MCTS model
reflects possible resistance to RGD4C.AAVP’s penetra-
tion to reach the target cells, due to their metabolic
activities, physical characteristics (hypoxia and lack of
vascularization) and differential regulation when com-
pared to 2D models [23]. Because cell monolayers lack
the complexities of 3D tumors, they are more susceptible
to therapy in vitro. By demonstrating the effectiveness of
ECM modulation in enhancing RGD4C.AAVP-meditaed
gene transfer in an MCTS setting, we show that our
strategy of ECM depletion is relevant for in vivo gene
based therapies.
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bining ECM depletion with HSVtk-GCV therapy. A
prominent problem with cancer gene therapy is incom-
plete eradication of tumors, which frequently translates
into cancer recurrence [51, 52]. ECM depletion allowed
significant eradication of tumor cells by RGD4C.AAVP
gene therapy, which demonstrates its potential as a
therapeutic strategy for future studies.Conclusions
ECM depletion greatly enhances gene transfer of phage-
derived vectors to deliver therapeutic genes specifically
to cancer cells. We provide evidence for how the ECM
plays physical and kinetic roles in impeding successful
cancer cell binding and entry of RGD4C.AAVP and
subsequent gene transfer by this phage vector, and
potentially other virus-based delivery strategies. By
eliminating the external barrier of tumors and increasing
vector transduction at multiple stages, this strategy may
improve the penetration of gene therapy vectors into
solid tumors. With many biologically safe inhibitors and
ECM-depleting enzymes becoming available, this
strategy warrants further clinical investigation. Here, we
provide evidence that ECM depletion is a clinically
translatable strategy with great potential to enhance
RGD4C.AAVP-guided cancer therapy.Material and methods
Cell culture
Rat 9L gliosarcoma cells were a gift from Dr Hrvoje
Miletic (University of Bergen, Norway) and human M21
Melanoma cells were provided by Dr David Cheresh
(University of California, La Jolla). Human LN229 and
SNB19 glioblastoma cells were provided by Dr Nelofer
Syed (Imperial College London, UK), LNCaP prostate
cancer cell line was a gift from Dr Paul Mintz (Imperial
College London) and the mouse C2C12 myoblast cell line
was provided by Dr Francesco Muntoni (University
College London, UK). The human breast cancer MCF-7
and glioblastoma U87 cell lines were from Cancer Re-
search UK. Cells were sustained in Dulbecco’s Modified
Eagle’s Medium (DMEM, Sigma) supplemented with
10 % Fetal Bovine Serum (FBS, Sigma), L-Glutamine
(2 mM, Sigma), Penicillin (100 units/ml, Sigma) and
Streptomycin (100 μg/ml, Sigma). The C2C12 cells
were grown in 20 % FBS. Cells were maintained at
37 °C in a humidified atmosphere supplemented with
5 % CO2. Collagenase from Clostridium histolyticum
(Type I, ≥125 CDU/mg, Sigma) and hyaluronidase
from bovine testes (Type I-S, 400-1000 units/mg,
Sigma) were solubilized in phosphate buffered saline
(1x PBS, Sigma).Immunostaining
Immunostaining experiments were performed as pre-
viously described [28]. Brief, cells were seeded on
18 mm2 coverslips in 12-well plates and allowed to
proliferate until 70-80 % confluence. Cultures were
then treated with enzymes as indicated, washed with
PBS, and fixed in 4 % PFA in PBS for 10 min at room
temperature. Next, cells were quenched with 50 mM
Ammonium Chloride (NH4Cl), washed with PBS and
blocked with PBS containing 2 % bovine serum
albumin (BSA) for 30 min. Cells were incubated with
mouse anti-fibronectin or anti-laminin antibodies (BD
Biosciences) at 1:200 dilution overnight at 4 °C, or 1 h
at room temperature with a rabbit anti-αv integrin (di-
luted 1:50). Then, cells were incubated with secondary
AlexaFluor-conjugated antibodies (diluted 1:750) and
with 4',6-diamidino-2-phenylindole (DAPI) (diluted
1:2000 in 1 % BSA-PBS) for 1 h at room temperature.
Finally, cells were mounted in Prolong Gold antifade
mounting medium (Invitrogen) and images were ob-
tained using a fluorescent microscope (Nikon Eclipse
TE2000U) and analysed by Openlab imaging software.
Hyaluronic acid (HA) ELISA
HA ELISA was performed as previously described [53].
Briefly, samples or standard umbilical cord HA (Sigma)
at various concentrations (19–10,000 ng/ml) in PBS
pH 7.4, were added to 1.5 ml plastic tubes containing
biotinylated hyaluronic acid binding protein (HABP,
1:200 in 0.05 M Tris–HCl buffer, pH 8.6). The tubes
were incubated at room temperature for 1 h, then sam-
ples were added to the microplate, which was pre-coated
with umbilical cord HA (100 μl/well of 10 mg/ml), and
blocked with 1 % BSA (150 μl/well). The plate was then
incubated at room temperature for 1 h. The wells were
subsequently washed and 100 μl of peroxidase-
conjugated anti-biotin antibody (Sigma) were added.
The plate was incubated at room temperature for
another hr. The reaction was stopped with 50 μl/well of
4 M sulfuric acid and the absorbance was determined
using a microplate reader (Molecular Devices) at 492/
690 nm. The concentration of HA in samples was calcu-
lated by reference to a standard curve.
Collagen depletion assay (Sirius Red)
Collagenase from Clostridium histolyticum (Type I, ≥125
CDU/mg, Sigma) was solubilized in 1x PBS. Tumor cells
were seeded in 12-well plates at a density of 120,000
cells/well and cultured for 72 h until confluence. Cells
were then washed with PBS and 500 μl of 0.2 mg/ml
collagenase in serum free media was added to the cells
and left to incubate at 37 °C for 1 h. Next, both cells and
supernatant were processed as different samples in a
collagen I detection assay. The assay was conducted
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the manufacturer’s instructions of a Sirius Red Total
Collagen Detection Kit (Chondrex, Inc.), with final mea-
surements obtained through a Promega plate reader.
AAVP diffusion assay
200 μl of ECM Gel from Engelbreth-Holm-Swarm
murine sarcoma (Sigma) at 2.5 mg/ml or 5.0 mg/ml
were added to a 48-well plate and allowed to set at 37 °C.
In the meantime fluorescently-tagged RGD4C.AAVP was
prepared at a concentration of 5 μg/ml. 50 μl of the
RGD4C.AAVP solution were taken up in a pipette tip,
which was inserted at a fixed position into the ECM-gel
matrix and left to diffuse through the material for 1 h.
Measurements were obtained at 1 h post diffusion and at
30 min intervals thereafter.
AAVP production and purification
AAVP bacteriophages were generated as previously re-
ported [54], by inserting an AAV mammalian viral
gene transfer cassette into the fUSE5 plasmid derived
from the fd-tet bacteriophage. Reporter or therapeutic
genes were carried by the cassette, driven by a
Cytomegalovirus (CMV) promoter. Targeting and spe-
cificity were achieved through genetic manipulation
and display of the RGD4C peptide on the pIII minor
coat protein conferring tumor-targeting properties
[54]. AAVPs were produced and purified from the
culture supernatant of Escherichia Coli K91 host
bacteria as previously reported [54]. Isolated AAVPs
were sterile-filtered through 0.45 μm filters and titration
levels were quantified using a photospectrophotometer
(NanoDrop, Thermo Scientific).
Generation of fluorescently-labelled RGD4C.AAVP
RGD4C.AAVP phage particles (1x1013) were conjugated
to fluorescein isothiocyanate (FITC) for 1 h at room
temperature in the dark [55]. Then the phage was puri-
fied by three consecutive polyethyleneglycol precipita-
tions, titrated as described above. Phage labelling was
confirmed by double-staining using a rabbit anti-phage
antibody (Sigma). We have previously confirmed that
the fluorescently-labelled phage retains target specificity
and cancer cell transduction (unpublished data).
AAVP internalization
Internalization assay was carried out as previously
described [28]. After cell treatment with optimized con-
centrations of the enzymes, cells were treated with
vectors for 4 h at 37 °C, then placed on ice to stop endo-
cytosis and washed 3 times with PBS to remove
unbound vectors. Surface bound vectors were removed
by trypsinization after which cells were pelleted by centri-
fugation at 2000 rpm for 5 min and fixed in 4 %paraformaldehyde (PFA) for 10 min at room temperature.
Untreated cells were used as negative controls. To detect
internalised phage-derived vectors, cells were blocked with
0.1 % saponin in 2 % bovine serum albumin in PBS (BSA-
PBS) for 30 min followed by staining with rabbit anti-
phage antibody (diluted 1:1000) in 0.1 % saponin in 1 %
BSA-PBS for 1 h at room temperature. Cells were pelleted
and re-suspended three times in 0.1 % saponin in 1 %
BSA-PBS, then incubated with goat anti-rabbit AlexaFluor-
647 (diluted 1:500) for 1 h at room temperature. Finally,
cells were washed twice with 0.1 % saponin-PBS and re-
suspended in PBS before analysis.
Fluorescence-activated cell sorting (FACS) analysis
was carried out using a FACscalibur Flow cytometer
(BD Biosciences) equipped with an argon-ion laser
(488 nm) and red-diode laser (635 nm). The mean
fluorescence intensity was measured for at least
10,000 gated cells per triplicate well. Results were ana-
lysed using Flojo (TreeStar) software.AAVP transduction
Transduction of cells with vectors were carried out as
we previously described [54]. Brief, 10,000–20,000
cells/well were seeded in 48-well plates and cultured
for 48-72 h to achieve 70–80 % confluence. The cells
were washed, then collagenase or hyaluronidase or
combination of both enzymes in serum free media were
added (as indicated) to the cells for 1 h at 37 °C before
the enzyme-containing medium was removed. 110 μl of
serum-free media with AAVP (as indicated) was then
applied followed by incubation at 37 °C for 4 h, 400 μl
of complete medium were subsequently added to the
cells and left for 72 h at 37 °C. For transduction using
RGD4C.AAVP/HSVtk, DEAE.DEXTRAN (60 ng/ 1 μg
AAVP) was used to enhance gene transduction in line
with our previously established protocol and findings
[16]. The cationic polymer does not affect cell viability
or specificity of the RGD4C.AAVP vector [16].Determination of tumor cell killing in vitro
Cells were seeded in 48-well plates and incubated for
48 h to reach 80 % confluence. Then, cultures were
treated with collagenase or hyaluronidase enzymes or
combination of both, as indicated. Enzyme solutions
were removed from cultures and washed with PBS
before treatment with AAVP vectors carrying the Herpes
Simplex Virus-thymidine kinase (HSVtk) gene. Ganciclovir
(GCV, Sigma) was added to the cells (40 μM) at day 3 post
vector transduction and renewed daily. Viable cells were
monitored under microscope and cell viability was mea-
sured at day three post GCV treatment by using the
trypan blue exclusion method (Sigma). When treating the
M21-tk cell population stably expressing the HSVtk gene,
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Reporter gene assays
Quantification of luciferase expression from cells trans-
duced with AAVP-Luc, was performed as described
[16]. Medium was aspirated before the addition of
110 μl of Glo Lysis buffer, 1x (Promega). 50 μl of the
cell lysate was then transferred to a 96-well white
opaque microplate (BD Falcon) and mixed with an equal
volume of Steady-Glo® luciferase substrate (Promega) for
luciferase and read with a Promega Glomax plate reader.
Luciferase expression was normalized to 1 μg protein
levels determined by the Bradford assay (Sigma) and data
presented as relative luminescence units (RLU). GFP
expression was visualized using a Nikon Eclipse TE2000-
U fluorescence microscope, as were morphological obser-
vations of cell monolayers.
Cell viability assays (CellTiter Glo)
Cells were seeded, treated and transduced in line with
the cell viability assay for trypan blue exclusion
method. However, a bioluminescence assay for cell via-
bility (CellTiter Glo, Promega) was used according to
the manufacturer’s instruction. The CellTiter Glo assay
is a luciferase-based assay to measure cell viability
based on available adenosine triphosphate in the cell
lysate.
Multicellular tumor spheroids (MCTS) culture and
treatment
MCTS were seeded in 96-well ultra-low attachment
surface plates (Corning) from trypsinized monolayer
cultures at an optimized cell suspension density [56] of
0.5 x 104 cells/ml in 200 μl. They were then incubated
for 48 h at 37 °C prior to any treatment. Media was
completely removed before the application of 110 μl of
enzyme/serum-free medium mixture and left to incubate
at 37 °C for 1 h. The enzyme-supplemented medium
was then removed and the spheroids were washed
with PBS before transduction with AAVP/Luc vectors
(in 110 μl of serum-free medium) for 4 h at 37 °C.
Following transduction, 100 μl of complete media
were added to make up a total volume of 200 μl and
the cells were left to develop gene expression over a
72 h incubation period at 37 °C.
For MCTS luciferase assays, media was removed and
15 μl of Glo Lysis buffer was added to one spheroid per
well. The MCTS were then incubated for 30 min. 10 μl
of cell lysate/well from each spheroid per experimental
condition were taken from 4 wells and combined to
make up 40 μl of total volume. This was mixed in a 1:1
ratio together with the Steady-Glo® luciferase substrate
and left 10 min before measurement in the Promegaplate reader. The luminescence signal was then normal-
ized to 1 μg protein levels determined by the Bradford
assay.
Losartan treatment
Various losartan concentrations of 0 μM, 20 μM, 50 μM,
100 μM, 150 μM and 200 μM were applied in serum-
free media to cells and left overnight in an incubator at
37 °C. The following day, losartan-containing media was
removed and cells were transduced with vectors as
described above. Luciferase assays were carried out at
72 h post-transduction.
Statistical analyses
Data are expressed as mean ± standard error of the
mean (s.e.m.) and analysed using student’s t test when
comparing two groups. To compare more than two
groups, we used one-way ANOVA and post hoc Turkey
tests. P values were considered significant when <0.05
and denoted as follows: *p < 0.05, **p < 0.01, ***p < 0.001.
Statistical analyses were performed using the GraphPad
Prism software (version 5.0).
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